Core Insights - The event "Industry Towards New · Intelligent Creation Suzhou - 2025 Suzhou Listed Companies Investor Reception Day" was successfully held, focusing on the latest dynamics in the capital market and the high-quality development of listed companies in Suzhou [1] Group 1: Event Overview - The event aimed to build an efficient communication platform between listed companies and investors, enhancing the investment value and development quality of Suzhou listed companies [1] - The event was guided by the Suzhou Municipal Financial Management Bureau and organized by the Suzhou Listed Companies Association, with support from various financial institutions [1] Group 2: Economic Performance - As of the end of Q3, Suzhou had over 270 listed companies, ranking among the top in the country, with A-share companies achieving revenues exceeding 660 billion yuan and a net profit growth of 16.37% year-on-year [2] - Emerging industries such as high-end manufacturing, new energy, and semiconductors are driving regional economic growth [2] Group 3: Future Projections - By 2025, Suzhou is projected to add 9 new domestic A-share listed companies, leading among major cities in China, with a total of 281 listed companies and an A-share market capitalization exceeding 2.5 trillion yuan [3] - The event highlighted the importance of enhancing information disclosure and fostering a transparent and responsible public image among listed companies [3] Group 4: Strategic Insights - The event featured discussions on mergers and acquisitions as a key strategy for companies to overcome development bottlenecks and achieve rapid growth [4] - Strategies for companies aiming to enter the international capital market were shared, providing detailed guidance for potential IPOs [4] Group 5: Investor Engagement - The event facilitated active engagement between investors and company executives, with 435 questions posed by investors and a response rate of 82.53% [5] - The establishment of the "Panorama Jiangsu Capital Reception Hall" aims to provide ongoing services for regional capital and industry integration [5]

Core Viewpoint - The company Muyuan Foods has re-submitted its H-share listing application to the Hong Kong Stock Exchange after its initial application failed earlier this year, indicating a strong urgency to go public and enhance its global market credibility [1][3]. Company Strategy - Muyuan Foods aims to expand its international presence, having established a wholly-owned subsidiary in Vietnam and invested 3.2 billion yuan in a high-tech breeding project, which will eventually support a breeding stock of 64,000 sows and produce 1.6 million market pigs annually [5]. - The company has also signed a strategic cooperation agreement with Charoen Pokphand Group to explore global synergies in feed and slaughtering sectors [5]. Financial Performance - For the first three quarters of 2025, Muyuan Foods reported revenue exceeding 100 billion yuan, reaching 111.79 billion yuan, a year-on-year increase of 15.52%, and a net profit of 14.779 billion yuan, up 41.01% [5]. - However, the third quarter saw a decline in performance, with revenue of 35.327 billion yuan, down 11.48% year-on-year, and net profit of 4.249 billion yuan, a decrease of 56%, primarily due to low industry pork prices [6]. Industry Context - The national breeding sow inventory stands at 40.35 million, exceeding the normal holding capacity by 3.5%, with pork consumption expected to decrease by an average of 0.5% annually until 2033 [8]. - The capital market has shown valuation discrepancies, which contributed to the initial IPO failure, with profit forecasts for 2025 varying significantly among analysts [8]. Future Outlook - As the peak pork consumption season approaches in the fourth quarter, there is potential for a moderate recovery in pork prices [8]. - Muyuan Foods aims to leverage its cost advantages and industry chain layout to mitigate cyclical risks in the industry while seeking favorable valuations in the Hong Kong market [8].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for five companies, including Jingcun Technology, which is preparing for an IPO on the Hong Kong Stock Exchange [1][2]. Group 1: Supplementary Material Requirements - Jingcun Technology is required to clarify issues related to equity changes, shareholder status, and business operations [1]. - The CSRC has requested a legal opinion from lawyers regarding the company's historical shareholding arrangements and the fairness of its employee stock ownership plan [1][2]. - The company must explain the implications of its actual controller's arrangements on control changes before and after the IPO [2]. Group 2: Business Operations - Jingcun Technology specializes in embedded storage products, including DRAM-based products (DDR, LPDDR) and NAND Flash-based products (eMMC, UFS) [3]. - The company also offers solid-state drives and memory modules, along with testing and storage technology services for clients [3].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has approved Beijing Xiantong International Pharmaceutical Technology Co., Ltd. to issue up to 9,259,900 overseas listed ordinary shares and to list on the Hong Kong Stock Exchange, along with the conversion of 34,466,214 domestic unlisted shares into overseas listed shares by 95 shareholders [1]. Company Overview - Xiantong Pharmaceutical is a leader in the Chinese radiopharmaceutical market, focusing on the development and commercialization of innovative radiopharmaceuticals with the potential to be the first listed or best-in-class in China [1]. - The company is recognized as the first in China to obtain marketing approval for innovative radiopharmaceuticals, to receive production licensing as a Marketing Authorization Holder (MAH), and to complete clinical trials for therapeutic radioligands accepted by the National Medical Products Administration (NMPA) [1]. Shareholder Participation - A total of 95 shareholders are involved in the conversion of shares, with significant contributions from various investment funds and individuals, including: - Xu Xingsheng: 3,343,071 shares - Jiangsu Jiequan Chengda Equity Investment Center: 2,959,381 shares - Jinshi Manufacturing Transformation and Upgrading New Materials Fund: 2,276,447 shares - China State-Owned Enterprises Structural Adjustment Fund II: 1,707,335 shares [1][2].

Core Viewpoint - Kexing Biopharmaceutical Co., Ltd. (referred to as "Kexing Pharmaceutical") has officially listed in Hong Kong after nearly five years of being on the A-share market, marking the beginning of its "A+H" dual-platform financing strategy. However, the company faces multiple challenges, including operational bottlenecks, increasing debt pressure, and governance issues that have raised market confidence concerns [1][2]. Financial Performance - Kexing Pharmaceutical's revenue has shown limited growth in recent years, with significant fluctuations in net profit. The operating revenues for 2022, 2023, 2024, and the first half of 2025 were 1.316 billion, 1.259 billion, 1.407 billion, and 700 million respectively, while net profits were -93 million, -195 million, 27 million, and 79 million respectively. Notably, in the first three quarters of 2025, the revenue reached 1.148 billion, a year-on-year increase of 10.54%, with a net profit of 111 million, marking a staggering year-on-year growth of 547.7% [3][5]. Product and Market Dynamics - The sustainability of Kexing Pharmaceutical's growth is questioned, as 80% of its revenue comes from four core products. The revenue from these products has remained stagnant between 1.2 billion and 1.3 billion from 2022 to 2024. The company's gross margin has also been declining, from 75.4% in 2022 to 63.6% in the first half of 2025 [7][8]. Governance and Compliance Issues - Kexing Pharmaceutical has faced significant governance and compliance issues, including receiving a regulatory warning for inaccurate information disclosure. The company had discrepancies in its earnings forecasts and failed to maintain consistent voluntary disclosures. Additionally, it mismanaged raised funds by investing in non-principal-protected products, which is against regulatory guidelines [9][10]. Shareholder Actions - Prior to the IPO, Kexing Pharmaceutical's controlling shareholder, Deng Xueqin, significantly reduced his holdings, cashing out over 1 billion in just five months. This raised concerns about shareholder intentions and market trust, especially as the company's total market value is only 6.78 billion [11][15].

【已完成四轮融资募集资金超190亿元 阿维塔递交港股IPO申请】2025年11月27日，阿维塔科技宣布，正式向香港联合交易所递交上市申请。《中国经营 报》记者了解到，此前阿维塔已经完成了四轮融资，募集资金超过190亿元，其中，C轮融资金额超过110亿元，是当年度国内最大的单笔融资。同时，阿维 塔还率先以115亿元入股引望，占股10%，与华为构建起以资本为纽带的新型战略合作关系。本次赴港上市所募集资金将主要用于产品开发、平台和技术开 发、品牌建设、销售服务网络建设，以及补充运营资金。（中经记者 石英婧 上海报道） 来源：中国经营报 ...

Core Viewpoint - The article discusses the recent IPO of Kexing Pharmaceutical Co., Ltd. in Hong Kong, highlighting the challenges it faces in gaining market trust due to governance issues, financial performance, and the actions of its controlling shareholder [1][5][19]. Financial Performance - Kexing Pharmaceutical's financial data shows a transition from continuous losses to a turnaround, with revenues of 1.316 billion, 1.259 billion, 1.407 billion, and 700 million yuan for the years 2022, 2023, 2024, and the first half of 2025 respectively, while net profits fluctuated from -93 million to 79 million yuan during the same period [6][7]. - In the first three quarters of 2025, the company reported a revenue of 1.148 billion yuan, a year-on-year increase of 10.54%, and a net profit of 111 million yuan, reflecting a significant growth of 547.7% [7]. - The growth in revenue is attributed to the expansion into overseas markets, with overseas revenue increasing from 160 million yuan in 2022 to 224 million yuan in 2024, and reaching 177 million yuan in the first three quarters of 2025, accounting for 25.9% of total revenue [8]. Product and Market Challenges - Kexing Pharmaceutical's core products, which account for 80% of its revenue, are facing growth limitations, with a significant reliance on four main products that contributed 98.9%, 96.1%, 89.5%, and 79.5% of revenue from 2022 to the first half of 2025 [9][10]. - The overall gross margin has been declining, with rates of 75.4%, 70.8%, 68.7%, and 63.6% from 2022 to the first half of 2025 [11]. Governance and Compliance Issues - The company has faced regulatory scrutiny, receiving a warning letter for issues related to information disclosure and improper use of raised funds, including investing in non-principal-protected products [13][17]. - There were significant discrepancies in performance forecasts, with the 2023 annual profit forecast being significantly off from the actual results, leading to regulatory concerns about the accuracy of disclosures [14][15]. Shareholder Actions - Prior to the IPO, the controlling shareholder, Deng Xueqin, sold shares worth over 1 billion yuan, raising concerns about potential shareholder cash-out and its impact on market confidence [19][22][23].

11月27日，安永发布2025年《中国内地和香港IPO市场回顾及展望》报告。报告指出，A股和香港市场 全年IPO数量和筹资额占全球总量的16%和33%。其中，A股市场整体稳中有进，港交所融资额位居全球 交易所榜首，预计全年港股上市新股数量超百只，融资额2800亿港元。 报告显示，大型IPO项目上市成为推动港股崛起的关键因素，其中来自A股的"A+H"及"A拆H"企业贡献 突出，全年预计超过20家A股公司在港首发上市，合计募资超过1700亿港元。 安永大中华区上市服务主管合伙人何兆烽表示："上半年国际资本持续涌入香港市场，南下资金加速流 入，推动港股投资者结构从'外资主导'转向'内外资双轮驱动'。虽然面临阶段性震荡，但港股整体呈现 上行趋势，并在龙头企业、市场政策、外部环境多重作用下实现规模增长与结构升级。" 行业结构上，新消费与硬科技成为推动港股上市活动的"双引擎"。"科企专线"等政策落地，为更多高潜 力科技企业提供了快速上市通道。安永大中华区TMT行业联席主管合伙人李康表示："当前，港股诸多 改革举措展现了制度灵活性和创新包容性，可以在上市、交易、产品及资金流动等多个维度，提升港股 市场的活力和竞争力。今年， ...

Core Insights - The Hong Kong IPO market has seen a significant presence of biopharmaceutical companies, with most listing under the HKEX Chapter 18A for unprofitable biotech firms, achieving strong first-day performance with many stocks rising over 100% [1] - The geographical distribution of these listings is concentrated, with 13 out of 19 biopharmaceutical companies coming from the Yangtze River Delta region, which includes 7 from Jiangsu, 4 from Zhejiang, and 2 from Shanghai [1] - The Yangtze River Delta contributes 30% of the national biopharmaceutical output, 30% of drug sales, and 70% of domestically produced Class 1 new drugs, with an industry value exceeding 1 trillion [1] - Additionally, 6 companies have listed under HKEX Chapter 18C for specialized technology firms, with 3 of these from the Guangzhou-Shenzhen area [1] - Market analysis suggests that as new first-tier cities enhance their IPO cultivation efforts, combined with the Hong Kong market's inclination towards specialized technology sectors, future mainland IPOs are expected to exhibit a "core leading, multi-point blossoming" trend [1] - Local governments are encouraged to align their local industry characteristics with the demands of the Hong Kong stock market [1]

市场分析人士指出，随着武汉、成都、西安等新一线城市加大辖内企业上市培育力度，以及港股对特专 科技、绿色经济等领域的持续倾斜，未来内地赴港IPO地图有望呈现"核心引领、多点开花"的态势。 2025年的港股市场正迎来久违的"IPO盛宴"。截至11月26日，港交所以2582.75亿港元的IPO募资额稳居 全球交易所榜首，同比增幅超257%。而在89家新上市公司中，地域分布的"马太效应"愈发明显——上 海、广东、江苏、浙江四地贡献了超半数的港股上市企业，成为港股IPO的核心策源地。 这幅清晰的港股IPO地图背后，是政策扶持、产业积淀与资本嗅觉的三重共振。对于地方政府而言，如 何将本地产业特色与港股市场需求精准对接，将成为培育下一批上市企业的关键命题。 四省市企业占据半壁江山 从省份维度看，2025年港股IPO的"第一梯队"界限清晰。上海以14家上市企业的数量独占鳌头，广东以 12家紧随其后，江苏与浙江则各有11家企业登陆港股，四省市合计贡献48家，占今年港股上市企业总数 的53.93%，占据半壁江山。 上述四省市均是当前国内的经济强省强市，也是市场活力和创新投入靠前的省市。国家统计局发布的 《2024年全国科技经费投 ...